Showing results (61-70 of 104) with videos related to
Sort By:
Pageof 11
BMC Cancer|November 13, 2024
Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinomaRalf Gutzmer, Ulrike Leiter, Peter Mohr, et al.Plos One|October 2, 2015
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?Joanna Mangana, Phil F Cheng, Katja Schindler, et al.Journal of Cancer Research and Clinical Oncology|June 16, 2017
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumabC Brüggemann, M C Kirchberger, S M Goldinger, et al.Cancer Immunology, Immunotherapy : CII|June 14, 2016
Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysisMarkus V Heppt, Thomas K Eigentler, Katharina C Kähler, et al.International Journal of Cancer|March 15, 2026
Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO studyRalf Gutzmer, Michael Weichenthal, Thomas Eigentler, et al.European Journal of Cancer (Oxford, England : 1990)|November 20, 2018
Myositis and neuromuscular side-effects induced by immune checkpoint inhibitorsAlvaro Moreira, Carmen Loquai, Claudia Pföhler, et al.European Journal of Cancer (Oxford, England : 1990)|April 3, 2021
Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology GroupImke Grimmelmann, Michael Momma, Lisa Zimmer, et al.European Journal of Cancer (Oxford, England : 1990)|April 6, 2021
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete responseFlorentia Dimitriou, Anne Zaremba, Clara Allayous, et al.European Journal of Cancer (Oxford, England : 1990)|December 12, 2025
Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapyS Dugas-Breit, A Forschner, M Erdmann, et al.Journal of Cancer Research and Clinical Oncology|May 14, 2024
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspectiveKatharina C Kähler, Ralf Gutzmer, Yenny Angela, et al.Pageof 11